Published in JACC Cardiovasc Interv on February 01, 2009
Trends in the use of percutaneous ventricular assist devices: analysis of national inpatient sample data, 2007 through 2012. JAMA Intern Med (2015) 1.48
Cardiogenic shock in ACS. Part 2: Role of mechanical circulatory support. Nat Rev Cardiol (2012) 1.08
Temporary mechanical circulatory support: a review of the options, indications, and outcomes. Clin Med Insights Cardiol (2015) 0.97
The Impella Recover 2.5 and TandemHeart ventricular assist devices are safe and associated with equivalent clinical outcomes in patients undergoing high-risk percutaneous coronary intervention. Catheter Cardiovasc Interv (2013) 0.87
Outcomes of pre-emptive and rescue use of percutaneous left ventricular assist device in patients with structural heart disease undergoing catheter ablation of ventricular tachycardia. J Interv Card Electrophysiol (2016) 0.86
Central extracorporeal life support with left ventricular decompression for the treatment of refractory cardiogenic shock and lung failure. J Cardiothorac Surg (2014) 0.80
Transapical miniaturized ventricular assist device: design and initial testing. J Thorac Cardiovasc Surg (2011) 0.80
Mechanical circulatory support in acute cardiogenic shock. F1000Prime Rep (2014) 0.80
New Impella Cardiac Power Device Used in Patient with Cardiogenic Shock due to Nonischemic Cardiomyopathy. Int J Angiol (2014) 0.79
Percutaneous Mechanical Support in Cardiogenic Shock: A Review. Clin Med Insights Cardiol (2015) 0.79
Use of Mechanical Circulatory Support in Percutaneous Coronary Intervention in the United States. Am J Cardiol (2015) 0.78
Use of impella ventricular assist device in patients with severe coronary artery disease presenting with cardiac arrest. Int J Angiol (2012) 0.77
Percutaneous Mechanical Ventricular Support in Acute Cardiac Care: A UK Quaternary Centre Experience Using 2.5L, 3.8L and 5.0L Impella Catheters. Cardiol Ther (2014) 0.77
The effect of combined treatment with Impella(®) and landiolol in a swine model of acute myocardial infarction. J Artif Organs (2012) 0.76
Percutaneous ventricular assist devices: new deus ex machina? Minim Invasive Surg (2011) 0.76
Upscaling cardiac assist devices in decompensated heart failure: Choice of device and its timing. Indian Heart J (2016) 0.75
Percutaneous Hemodynamic Support (Impella) in Patients with Advanced Heart Failure and/or Cardiogenic Shock Not Eligible to PROTECT II Trial. Int J Angiol (2013) 0.75
High-risk percutaneous coronary intervention with Impella CP hemodynamic support. A case series and method presentation. Postepy Kardiol Interwencyjnej (2017) 0.75
Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in India. Indian Heart J (2017) 0.75
Percutaneous Ventricular Assist Devices: A Health Technology Assessment. Ont Health Technol Assess Ser (2017) 0.75
Massive Atenolol, Lisinopril, and Chlorthalidone Overdose Treated with Endoscopic Decontamination, Hemodialysis, Impella Percutaneous Left Ventricular Assist Device, and ECMO. J Med Toxicol (2015) 0.75
High-risk acute coronary syndrome in a patient with coronary subclavian steal syndrome secondary to critical subclavian artery stenosis. Case Rep Cardiol (2014) 0.75
The Duration of Impella 2.5 Circulatory Support and Length of Hospital Stay of Patients Undergoing High-risk Percutaneous Coronary Interventions. Cardiol Res (2012) 0.75
Acute complication due to impella 2.5 device (superficial femoral artery thrombosis): managed successfully with novel aspiration thrombectomy catheter (pronto v3). Clin Med Insights Cardiol (2011) 0.75
Review of Venoarterial Extracorporeal Membrane Oxygenation and Development of Intracardiac Thrombosis in Adult Cardiothoracic Patients. J Extra Corpor Technol (2016) 0.75
Imaging of mechanical cardiac assist devices. J Clin Imaging Sci (2011) 0.75
Treating Refractory Cardiogenic Shock With the TandemHeart and Impella Devices: A Single Center Experience. Cardiol Res (2012) 0.75
Percutaneous left ventricular assist device in high risk percutaneous coronary intervention. J Thorac Dis (2016) 0.75
Use of a Vascular Sheath in the Axillary Artery as an Alternative Access Approach for Placing an Impella 5.0 Device. Tex Heart Inst J (2015) 0.75
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med (2012) 8.19
Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA (2012) 6.96
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35
Diagnostic accuracy of noninvasive coronary angiography using 64-slice spiral computed tomography. J Am Coll Cardiol (2005) 6.07
Percutaneous repair or surgery for mitral regurgitation. N Engl J Med (2011) 5.78
Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation (2007) 4.58
A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol (2007) 3.83
A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol (2002) 3.52
Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol (2004) 3.49
Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv (2011) 3.38
Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation (2012) 3.24
Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. Catheter Cardiovasc Interv (2010) 3.24
A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J (2009) 3.06
Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol (2012) 3.01
Nonemergency PCI at hospitals with or without on-site cardiac surgery. N Engl J Med (2013) 2.98
Presence of older thrombus is an independent predictor of long-term mortality in patients with ST-elevation myocardial infarction treated with thrombus aspiration during primary percutaneous coronary intervention. Circulation (2008) 2.96
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol (2009) 2.94
Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS One (2009) 2.89
Lack of association between migraine headache and patent foramen ovale: results of a case-control study. Circulation (2010) 2.88
Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation (2006) 2.63
A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52
Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med (2002) 2.52
Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation (2002) 2.52
iDASH: integrating data for analysis, anonymization, and sharing. J Am Med Inform Assoc (2011) 2.51
Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest (2008) 2.46
2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol (2008) 2.46
Fatal inhalational anthrax with unknown source of exposure in a 61-year-old woman in New York City. JAMA (2002) 2.46
A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. JACC Cardiovasc Interv (2009) 2.30
A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol (2009) 2.29
Fibrinolytic therapy: is it a treatment of the past? Circulation (2003) 2.27
Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv (2009) 2.24
Sex differences in medical care and early death after acute myocardial infarction. Circulation (2008) 2.17
Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA (2006) 2.16
Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol (2011) 2.15
Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J (2006) 2.14
Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol (2004) 2.14
A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation (2012) 2.08
Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv (2003) 2.06
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res (2010) 2.03
Characteristics of cerebrovascular accidents after percutaneous coronary interventions. J Am Coll Cardiol (2004) 2.03
Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation (2009) 2.02
Comparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of "falsification hypotheses" in observational studies of comparative effectiveness. J Am Coll Cardiol (2013) 2.01
Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation (2004) 1.96
The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol (2010) 1.94
Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol (2004) 1.91
Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur Heart J (2009) 1.90
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med (2012) 1.89
The changing pattern of coronary perforation during percutaneous coronary intervention in the new device era. J Invasive Cardiol (2004) 1.87
Simplified scoring system for predicting mortality after percutaneous coronary intervention. J Am Coll Cardiol (2003) 1.84
Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol (2004) 1.83
Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation (2004) 1.83
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol (2010) 1.80
Comparison of transcatheter and surgical aortic valve replacement in severe aortic stenosis: a longitudinal study of echocardiography parameters in cohort A of the PARTNER trial (placement of aortic transcatheter valves). J Am Coll Cardiol (2013) 1.79
Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol (2005) 1.77
Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol (2005) 1.73
Impact of multivessel coronary disease on long-term mortality in patients with ST-elevation myocardial infarction is due to the presence of a chronic total occlusion. Am J Cardiol (2006) 1.73
Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry. J Am Coll Cardiol (2008) 1.73
Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis. J Am Coll Cardiol (2005) 1.72
Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation (2004) 1.72
Extracorporeal membrane oxygenation as a bridge to emergency heart-lung transplantation in a patient with idiopathic pulmonary arterial hypertension. J Heart Lung Transplant (2008) 1.72
Gangliosides as components of lipid membrane domains. Glycobiology (2006) 1.71
Impact of public reporting and outlier status identification on percutaneous coronary intervention case selection in Massachusetts. JACC Cardiovasc Interv (2013) 1.71
The role of temporary biventricular pacing in the cardiac surgical patient with severely reduced left ventricular systolic function. J Thorac Cardiovasc Surg (2008) 1.70
Saphenous vein graft intervention. JACC Cardiovasc Interv (2011) 1.69
Mesenchymal stem cell injection induces cardiac nerve sprouting and increased tenascin expression in a Swine model of myocardial infarction. J Cardiovasc Electrophysiol (2003) 1.68
Multiple biomarkers at admission significantly improve the prediction of mortality in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol (2011) 1.68
Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation (2008) 1.68
Reporting trends and outcomes in ST-segment-elevation myocardial infarction national hospital quality assessment programs. Circulation (2013) 1.67
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol (2012) 1.66
Novel use of the Amplatzer septal occluder device in the percutaneous closure of ascending aortic pseudoaneurysms: a case series. Catheter Cardiovasc Interv (2007) 1.65
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv (2012) 1.65
Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv (2002) 1.64
Utility of lung ultrasound in predicting pulmonary and cardiac pressures. Eur J Heart Fail (2012) 1.63
Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes. Heart (2009) 1.62
Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). Am J Cardiol (2006) 1.62
Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol (2005) 1.62
Clinical experience with the TandemHeart percutaneous ventricular assist device. Tex Heart Inst J (2006) 1.62
Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract (2010) 1.62
European Registry of Carotid Artery Stenting: results from a prospective registry of eight high volume EUROPEAN institutions. Catheter Cardiovasc Interv (2012) 1.61
Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol (2004) 1.61
Treatment of coronary artery perforations complicating percutaneous coronary intervention with a polytetrafluoroethylene-covered stent graft. Am J Cardiol (2006) 1.59
Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation (2008) 1.59
N-glycolyl GM1 ganglioside as a receptor for simian virus 40. J Virol (2007) 1.59